FORMULATIONS OF AZAINDOLE COMPOUNDS

• US 20160250213A1
• Filed: 05/10/2016
• Published: 09/01/2016
• Est. Priority Date: 11/13/2013
• Status: Abandoned Application

• Current Assignee: Vertex Pharmaceuticals Incorporated
• Original Assignee: Vertex Pharmaceuticals Incorporated
• Inventors: Simone, Eric Arthur, Banda, Alamelu, Stavropoulos, Katherine, Sanghvi, Tapan
• Application Number:
  US15/150,497
• Publication Number:
  US 20160250213A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/351 not condensed with another ring
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 31/497 containing further heterocyclic rings
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses

Abstract

A pharmaceutical composition comprises: a) 5 wt % to 95 wt % of a HCl salt of Compound (1).xH₂O by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt % to 95 wt % of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/mL to 20 mg/mL of Compound (1) in water; and b) 0.01 M to 0.1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1) that includes the HCl salt of Compound (1).xH₂O and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HCl salt of Compound (1).xH₂O and the pH modifier to form 1 mg/mL to 20 mg/mL of Compound (1) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, and treating influenza each independently employ such pharmaceutical compositions.

Claims

1. A pharmaceutical composition comprising:

a) a HCl salt of Compound (1).xH₂O wherein Compound (1) is represented by the following structural formula;

2. The pharmaceutical composition of claim 1, wherein x is from 0.5 to 3.

3. The pharmaceutical composition of claim 2, wherein x is 0.5.

4. The pharmaceutical composition of any one of claims 1-3, wherein the HCl salt of Compound (1).xH₂O has a crystalline form.

5. The pharmaceutical composition of any one of claims 1-4, further comprising 10 wt % to 80 wt % of a filler by weight of the pharmaceutical composition.

6. The pharmaceutical composition of claim 5, wherein the filler comprises microcrystalline cellulose, lactose, or any combination thereof.

7. The pharmaceutical composition of any one of claims 1-6, further comprising 1 wt % to 10 wt % of a disintegrant agent by the weight of the pharmaceutical composition.

8. The pharmaceutical composition of claim 7, wherein the disintegrant agent comprises croscarmellose, crospovidone, polyplasdone, starch, metal starch glycolate, or any combination thereof.

9. The pharmaceutical composition of claim 8, wherein the disintegrant agent comprises croscarmellose sodium, polypladone, or any combination thereof.

10. The pharmaceutical composition of any one of claims 1-9, further comprising 0.1 wt % to 5 wt % of a binder by the weight of the pharmaceutical composition.

11. The pharmaceutical composition of claim 10, wherein the binder comprises polyvinyl pyrrolidone, starch, sugar, microcrystalline cellulose, hydroxy propyl methyl cellulose, hydroxy propyl cellulose, hydroxy ethyl cellulose, or any combination thereof.

12. The pharmaceutical composition of any one of claims 1-11, further comprising 0.5 wt % to 5 wt % of a lubricant by the weight of the pharmaceutical composition.

13. The pharmaceutical composition of claim 12, wherein the lubricant comprises metal stearate, metal stearyl fumarate, or any combination thereof.

14. The pharmaceutical composition of claim 13, wherein the lubricant comprises sodium stearyl fumarate, magnesium stearate, or any combination thereof.

15. The pharmaceutical composition of claim 14, wherein the lubricant comprises sodium stearyl fumarate.

16. The pharmaceutical composition of any one of claims 1-15, wherein the pharmaceutical composition comprises:

a) 20 wt % to 80 wt % of Form A of HCl salt of Compound (1).½

H₂O by the weight of the pharmaceutical composition;

b) 1 wt % to 10 wt % of the disintegrant agent by the weight of the pharmaceutical composition; and

c) 20 wt % to 80 wt % of the filler by the weight of the pharmaceutical composition.

17. The pharmaceutical composition of any one of claims 1-15, wherein the composition comprises:

a) 20 wt % to 80 wt % of Form A of HCl salt of Compound (1).½

H₂O by the weight of the pharmaceutical composition;

b) 1 wt % to 10 wt % of the disintegrant agent by the weight of the pharmaceutical composition;

c) 0.1 wt % to 5 wt % of the binder by the weight of the pharmaceutical composition; and

d) 20 wt % to 80 wt % of the filler by the weight of the pharmaceutical composition.

18. The pharmaceutical composition of any one of claims 1-15, wherein the composition comprises:

a) 20 wt % to 80 wt % of Form A of HCl salt of Compound (1).½

H₂O by the weight of the pharmaceutical composition;

b) 1 wt % to 10 wt % of the disintegrant agent by the weight of the pharmaceutical composition;

c) 0.1 wt % to 5 wt % of the binder by the weight of the pharmaceutical composition;

d) 20 wt % to 80 wt % of the filler by the weight of the pharmaceutical composition; and

e) 0.5 wt % to 5 wt % of a lubricant by the weight of the composition.

19. The pharmaceutical composition of any one of claims 1-15, wherein the composition comprises:

a) 35 wt % to 75 wt % of Form A of HCl salt of Compound (1).½

H₂O by the weight of the pharmaceutical composition;

b) 1 wt % to 7 wt % of the disintegrant agent by the weight of the pharmaceutical composition, wherein the disintegrant is selected from a croscarmellose, a crospovidone, polyplasdone, a metal starch glycolate, a starch, or any combination thereof;

c) 0.5 wt % to 2 wt % of the binder by the weight of the pharmaceutical composition, wherein the binder is selected from a polyvinyl pyrrolidone, a starch, a sugar, a microcrystalline cellulose, a hydroxy propyl methyl cellulose, a hydroxy propyl cellulose, or a hydroxy ethyl cellulose, or any combination thereof;

d) 25 wt % to 50 wt % of the filler by the weight of the pharmaceutical composition;

wherein the filler is selected from a microcrystalline cellulose, a lactose, a sorbitol, a cellulose, a calcium phosphate, a starch, or a sugar, or any combination thereof; and

e) 0.5 wt % to 3 wt % of a lubricant by the weight of the composition, wherein the lubricant is selected from a metal stearate, a metal stearyl fumarate, or any combination thereof.

20. The pharmaceutical composition of any one of claims 1-15, wherein the composition comprises:

a) 35 wt % to 75 wt % of Form A of HCl salt of Compound (1).½

H₂O by the weight of the pharmaceutical composition;

b) 3 wt % to 7 wt % of a disintegrant agent by weight of the pharmaceutical composition, wherein the disintegrant agent comprises croscarmellose;

c) 0.5 wt % to 2 wt % a binder by the weight of the pharmaceutical composition, wherein the binder comprises polyvinyl pyrrolidone;

d) 25 wt % to 50 wt % of a filler by the weight of the pharmaceutical composition;

wherein the filler comprises microcrystalline cellulose and lactose; and

e) 0.5 wt % to 3 wt % of a lubricant by the weight of the composition, wherein the lubricant comprises metal stearyl fumarate.

21. The pharmaceutical composition of any one of claims 1-15, wherein the composition comprises:

a) 35 wt % to 75 wt % of Form A of HCl salt of Compound (1).½

H₂O by the weight of the pharmaceutical composition;

b) 3 wt % to 7 wt % of a crosscarmellose by the weight of the pharmaceutical composition;

c) 0.5 wt % to 2 wt % of a polyvinyl pyrrolidone by the weight of the pharmaceutical composition;

d) 25 wt % to 50 wt % of the filler by the weight of the pharmaceutical composition;

wherein the filler comprises microcrystalline cellulose and lactose; and

e) 0.5 wt % to 3 wt % of sodium stearyl fumarate by the weight of the composition.

22. The pharmaceutical composition of any one of claims 1-15, wherein the composition comprises:

a) 35 wt % to 65 wt % of Form A of HCl salt of Compound (1).½

H₂O by the weight of the pharmaceutical composition;

b) 3 wt % to 7 wt % of crosscarmellose sodium by the weight of the pharmaceutical composition;

c) 0.5 wt % to 2 wt % of a polyvinyl pyrrolidone having an average molecular weight of 3,000 to 5,000 by the weight of the pharmaceutical composition;

d) 30 wt % to 40 wt % of a microcrystalline cellulose by the weight of the pharmaceutical composition;

e) 5 wt % to 10 wt % of lactose monohydrate by the weight of the pharmaceutical composition; and

f) 1 wt % to 3 wt % of sodium stearyl fumarate by the weight of the composition.

52. A method of reducing the amount of influenza viruses in a biological in vitro sample or in a subject, comprising administering to the sample or subject an effective amount of a pharmaceutical composition according to any one of claims 1-33.

53. A method of inhibiting the replication of influenza viruses in a biological in vitro sample or in a subject, comprising administering to the sample or subject an effective amount of a pharmaceutical composition according to any one of claims 1-33.

54. A method of treating influenza in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to any one of claims 1-33.

55. The method of any one of claims 52-54, further comprising co-administering one or more additional therapeutic agents to the sample or subject.

56. The method of claim 55, wherein the additional therapeutic agents comprise an anti-virus drug.

57. The method of claim 56, wherein the anti-virus drug comprises a neuraminidase inhibitor.

58. The method of claim 57, wherein the neuraminidase inhibitor comprises oseltamivir, zanamivir, or any combination thereof.

59. The method of claim 56, wherein the anti-virus drug comprises a polymerase inhibitor.

60. The method of claim 59, wherein the polymerase inhibitor comprises flavipiravir.

61. The method of any one of claims 52-60, wherein the influenza viruses are influenza A viruses.

62. A dosage regimen comprising administering to a subject an effective amount of a pharmaceutical composition according to any one of claims 1-22 in a dosage amount of 100 mg to 1,600 mg of HCl salt of Compound (1).xH₂O.

23. A pharmaceutical composition comprising:

a) 1 mg/mL to 20 mg/mL of Compound (1) in water, wherein Compound (1) is represented by the following structural formula;

24. The pharmaceutical composition of claim 23, wherein a source of Compound (1) is a HCl salt of Compound (1).xH₂O, wherein x is from 0 to 3.

25. The pharmaceutical composition of claim 24, wherein x is 0.5.

26. The pharmaceutical composition of claim 25, wherein the HCl salt of Compound (1).xH₂O is Form A of HCl salt of Compound (1).½

H₂O.

27. The pharmaceutical composition of any one of claims 23-26, wherein the pH modifier comprises NaOH, KOH, NH₄OH, HCl, a carbonate, a bicarbonate, a monobasic phosphate, a dibasic phosphate, an acetate, or any combination thereof.

28. The pharmaceutical composition of claim 27, wherein the pH modifier comprises a phosphate buffering agent.

29. The pharmaceutical composition of claim 28, wherein the phosphate buffering agent comprises monosodium phosphate, disodium phosphate, or any combination thereof.

30. The pharmaceutical composition of any one of claims 23-29, further comprising 1 wt % to 20 wt % of a complexing agent by weight of the pharmaceutical composition.

31. The pharmaceutical composition of claim 30, wherein the complexing agent comprises cyclodextrin, polysorbate, castor oil, or any combination thereof.

32. The pharmaceutical composition of claim 31, wherein the complexing agent comprises a cyclodextrin comprising an alpha cyclodextrin, a beta cyclodextrin, a gamma cyclodextrin, a hydroxypropyl-beta-cyclodextrin, a sulfo-butylether-beta-cyclodextrin, a polyanionic beta-cyclodextrin, or any combination thereof;

a polysorbate comprising a polyoxyethylene (20) sorbitan monoleate;

a castor oil comprising a polyoxy 40 hydrogenated castor oil, a polyoxy 35 castor oil, or any combination thereof;

or any combination thereof.

33. The pharmaceutical composition of any one of claims 23-32, further comprising dextrose, manitol, or any combination thereof.

34. A method of preparing a pharmaceutical composition, comprising:

providing a mixture of Compound (1) comprising;

a) 5 wt % to 95 wt % of a HCl salt of Compound (1).xH₂O by the weight of the pharmaceutical composition, wherein Compound (1) is represented by the following structural formula;

35. The method of claim 34, wherein the step of providing the mixture of Compound (1) comprises:

mixing HCl salt of Compound (1).xH₂O and one or more intra-granular excipients to provide granules of Compound (1), wherein the granules of Compound (1) comprise 60 wt % to 90 wt % of HCl salt of Compound (1).xH₂O by the weight of the granules and 10 wt % to 40 wt % of one or more excipients by the weight of the granules; and

mixing the granules of Compound (1) with one or more extra-granular excipients give a pharmaceutical composition comprising 15 wt % to 40 wt % of the one or more extra-granular excipients by weight of the pharmaceutical composition.

36. The method of claim 35, wherein the granules of Compound (1) comprise 10 wt % to 40 wt % of a filler by weight of the granules, the pharmaceutical composition comprises 15 wt % to 40 wt % of filler by weight of the pharmaceutical composition, or both.

37. The method of either of claim 35 or 36, wherein the filler comprises microcrystalline cellulose, lactose, or any combination thereof.

38. The method of claim 35, wherein the mixture of Compound (1) further comprises a binder, a disintegrant agent, a lubricant, or any combination thereof.

39. The method of claim 35, wherein the step of providing the mixture of Compound (1) comprises:

mixing

i) 70 wt % to 85 wt % of HCl salt of Compound (1).xH₂O by the weight of the granules of Compound (1); and

ii) one or more intra-granular excipient comprising 14 wt % to 25 wt % of the filler by the weight of the granules and 1 wt % to 5 wt % of the disintegrant agent by the weight of the granules to provide the granules of Compound (1); and

mixing the granules of Compound (1) with one or more extra-granular excipients comprising 15 wt % to 40 wt % of the filler by the weight of the pharmaceutical composition, 0.5 wt % to 5 wt % of the disintegrant agent by the weight of the pharmaceutical composition, and 0.5 wt % to 5 wt % of the lubricant by the weight of the pharmaceutical composition.

40. The method of claim 35, wherein the step of providing the mixture of Compound (1) comprises:

providing a binder solution comprising water and 0.5 wt % to 5 wt % of the binder by the weight of the granules of Compound (1);

providing an intra-granulation composition comprising

i) 70 wt % to 85 wt % of HCl salt of Compound (1).xH₂O by the weight of the granules of Compound (1); and

ii) an intra-granular excipient that includes 14 wt % to 25 wt % of the filler by the weight of the granules of Compound (1) and 1 wt % to 5 wt % of the disintegrant agent by the weight of the granules of Compound (1); and

mixing the binder solution and the intra-granulation composition to form the granules of Compound (1); and

mixing the granules of Compound (1) with one or more extra-granular excipients comprising 15 wt % to 40 wt % of the filler by the weight of the pharmaceutical composition, 0.5 wt % to 5 wt % of the disintegrant agent by the weight of the pharmaceutical composition, and 0.5 wt % to 5 wt % of the lubricant by the weight of the pharmaceutical composition.

43. The method of any one of claims 34-42, wherein the filler comprises microcrystalline cellulose, lactose, or any combination thereof.

44. The method of any one of claims 34-42, wherein the binder comprises hydroxyl propyl cellulose, polyvinyl pyrrolidone, or any combination thereof.

45. The method of any one of claims 34-44, wherein the disintegrant agent comprises croscarmellose sodium, crospovidone, sodium starch glycolate, or any combination thereof.

46. The method of any one of claims 38-45, wherein the lubricant comprises a metal stearate, a metal stearyl fumarate, or any combination thereof.

47. The method of any one of claims 38-46, wherein:

the binder comprises polyvinyl pyrrolidone having an average molecular weight of 3,000 to 5,000;

the filler comprises microcrystalline cellulose and lactose monohydrate;

the disintegrant agent comprises croscarmellose sodium; and

the lubricant comprises sodium stearyl fumarate.

48. The method of any one of claims 34-47, further comprising compressing the mixture of Compound (1) into a tablet.

41. The method of 40, wherein the step of mixing the binder solution and the pre-granulation composition comprises

i) feeding the intra-granulation composition into a twin screw extruder;

and

ii) introducing the binder solution into the twin screw extruder.

42. The method of claim 41, wherein the binder solution comprises 30 wt % to 50 wt % of water by weight of the intra-granulation composition.

49. A method of preparing a pharmaceutical composition, comprising:

mixing

a) a HCl salt of Compound (1).xH₂O, wherein Compound (1) is represented by the following structural formula;

50. The pharmaceutical composition of claim 49, wherein x is 0.5.

51. The pharmaceutical composition of claim 49, wherein the HCl salt of Compound (1).xH₂O is Form A of HCl salt of Compound (1).½

H₂O.